Cue Biopharma Appoints New CMO, Adds Director
Ticker: CUE · Form: 8-K · Filed: Jul 25, 2024 · CIK: 1645460
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointment
TL;DR
Cue Biopharma beefs up leadership with a new CMO and a board member.
AI Summary
On July 24, 2024, Cue Biopharma, Inc. announced the appointment of Dr. Anjana Shah as Chief Medical Officer and the election of Ms. Jennifer L. Morgan to its Board of Directors. The company also reported on its compensatory arrangements for certain officers.
Why It Matters
These appointments signal potential strategic shifts and leadership changes within Cue Biopharma, which could impact its drug development pipeline and overall corporate direction.
Risk Assessment
Risk Level: medium — Changes in key leadership roles and board composition can introduce uncertainty and signal strategic shifts, impacting investor confidence and future performance.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- Dr. Anjana Shah (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Morgan (person) — Elected to Board of Directors
- July 24, 2024 (date) — Date of earliest event reported
FAQ
What are the specific responsibilities of the newly appointed Chief Medical Officer, Dr. Anjana Shah?
The filing states Dr. Anjana Shah was appointed Chief Medical Officer, but does not detail her specific responsibilities beyond this title.
What is Ms. Jennifer L. Morgan's background and experience that led to her election to the Board of Directors?
The filing announces Ms. Jennifer L. Morgan's election to the Board of Directors but does not provide details on her background or experience.
Are there any changes to existing officer compensation arrangements being reported?
The filing indicates information regarding compensatory arrangements of certain officers, but specific details of changes are not provided in this summary.
What is the significance of the 'Other Events' item reported on July 24, 2024?
The filing lists 'Other Events' as an item information, but the specific nature of these events is not detailed in the provided text.
Does this filing indicate any financial performance updates for Cue Biopharma, Inc.?
This filing primarily concerns corporate events such as officer appointments and director elections, and does not include specific financial statements or performance updates.
Filing Stats: 1,082 words · 4 min read · ~4 pages · Grade level 15.3 · Accepted 2024-07-25 16:00:08
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market
Filing Documents
- cue-20240724.htm (8-K) — 61KB
- cue-ex99_1.htm (EX-99.1) — 26KB
- img239719762_0.jpg (GRAPHIC) — 27KB
- 0000950170-24-086476.txt ( ) — 268KB
- cue-20240724.xsd (EX-101.SCH) — 44KB
- cue-20240724_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 25, 2024, Cue Biopharma, Inc. (the "Company") announced the strategic prioritization of its autoimmune programs and organizational restructuring to strengthen operational efficiencies. As part of the organizational restructuring and to reduce the Company's annual cash burn, on July 24, 2024, Daniel R. Passeri, the Company's chief executive officer, voluntarily offered and agreed to reduce his 2024 annual base salary by 50%, effective immediately. In addition, on July 24, 2024, the Company's executive officers voluntarily offered and agreed to forgo any annual bonus earned for 2023 performance.
01
Item 8.01. Other Events. On July 25, 2024, the Company issued a press release announcing the strategic prioritization of its autoimmune programs and organizational restructuring to strengthen operational efficiencies, including an approximate 25% reduction in the Company's workforce. The Company anticipates these actions will extend its cash runway into mid-year 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the Company's business strategies, plans and prospects, including the potential benefits of the Company's program prioritization and realignment and workforce reduction, and the Company's projections regarding its annual cash burn and cash runway. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "promise" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this Current Report on Form 8-K regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the Company's ability to shift its focus to its autoimmune assets and achieve the cost savings that it is projecting; the Company's limited operating history, limited cash and a history of losses; the Company's ability to achieve profitability; potential setbacks in the Company's research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the Company's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; seriou
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated July 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cue Biopharma, Inc. Date: July 25, 2024 By: /s/ Daniel R. Passeri Name: Daniel R. Passeri Title: Chief Executive Officer